Suda Pharmaceuticals Ltd P/E
Quel est le P/E de Suda Pharmaceuticals Ltd?
Le P/E de Suda Pharmaceuticals Ltd est N/A
Quelle est la définition de P/E?
Le ratio cours / bénéfice est le rapport entre le prix des actions d'une entreprise et le bénéfice par action de l'entreprise calculé sur les douze derniers mois.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E des entreprises dans Health Care secteur sur ASX par rapport à Suda Pharmaceuticals Ltd
Que fait Suda Pharmaceuticals Ltd?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Entreprises avec p/e similaire à Suda Pharmaceuticals Ltd
- Viva Gold a P/E de N/A
- Parazero a P/E de N/A
- Orsted A/S Dk 10 a P/E de N/A
- Southern Hemisphere Mining a P/E de N/A
- Buderim a P/E de N/A
- BioVie a P/E de N/A
- Suda Pharmaceuticals Ltd a P/E de N/A
- GR Silver Mining a P/E de N/A
- Calyxt Inc a P/E de N/A
- Strip Tinning Plc Ord a P/E de N/A
- IBO Technology a P/E de N/A
- Luby`s a P/E de N/A
- Cranes Software International a P/E de N/A